Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSG-Fc
- Development stage
- Preclinical
- Lead developer
- Planet Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
BSG-Fc is a recombinant fusion protein (immunoadhesin) being developed by Planet Biotechnology for the treatment and prevention of malaria caused by *Plasmodium falciparum*. The molecule consists of the extracellular domain of human Basigin (BSG, also known as CD147) fused to an immunoglobulin Fc region. Basigin is the essential host receptor on erythrocytes that interacts with the *P. falciparum* Rh5 protein to facilitate parasite invasion. BSG-Fc acts as a decoy receptor, competitively binding to Rh5 on the parasite surface and preventing it from engaging with native Basigin on red blood cells, thereby inhibiting infection. The project is currently in the preclinical stage with research-grade protein available.
- Other names
- Basigin-FcBSG-fusion protein
02
Targets
PfRH5
Beyond the preview
Go deeper on BSG-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BSG-Fc.